Login to Your Account

Blood, Breast and Beyond

Finding JAK2's Partners in Crime Useful in Blood, Other Disorders

By Anette Breindl
Science Editor

Monday, December 17, 2012

ATLANTA – Nineteen years to the day after the activation of the JAK/STAT pathway by interferon was first described in the Dec. 9, 1993, issue of Nature, scientists at Incyte Corp. described the pathway from that description to the first approved inhibitor of the JAK/STAT pathway, Jakafi (ruxolitinib, Incyte Corp) at the American Society of Hematology (ASH) annual meeting last week.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription